Mounjaro by Eli Lilly Approved for China's State Insurance Coverage for Diabetes

Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.

Mounjaro Approved for China's Health Insurance

Starting January 1, Eli Lilly's Mounjaro will be included in China's state-managed health insurance program for individuals diagnosed with type 2 diabetes. The National Healthcare Security Administration announced this update on their website on Sunday.

Listing in the national reimbursement program broadens the availability of drugs to a larger population in China, which has 1.4 billion residents. However, increased sales are frequently offset by lower prices as a result of negotiations with the government.

Mounjaro, a once-weekly injectable medication, became available in China in January of this year. This followed the 2021 launch of Ozempic, a similar diabetes treatment from Novo Nordisk, a competing Danish pharmaceutical company.

Ozempic was initially added to China's reimbursement list in 2022.

Novo's annual report indicated that Ozempic sales in the greater China region totaled 5.76 billion Danish crowns ($898.5 million) in 2024.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Lilly has not yet disclosed the negotiated price of Mounjaro for diabetes treatment under China's reimbursement program. This figure is determined through negotiations with the government.

Mounjaro is also marketed in China for the treatment of obesity and obstructive sleep apnea. Health tracking apps like Shotlee can help monitor the effectiveness and potential side effects of treatments like Mounjaro.

During an October earnings call, Eli Lilly's international president, Patrik Jonsson, mentioned that the company had observed an "initial stocking" in markets outside the U.S. where Mounjaro had been introduced, with China, Brazil, Mexico, and India being the most significant in the second quarter.

Jonsson further stated that they have witnessed an increase in performance in those markets in the third quarter, along with continued strong performance on a global scale.

($1 = 6.4105 Danish crowns)

Source Information

Originally published by Yahoo! Finance.Read the original article →

Keep exploring

More on Mounjaro

Articles covering Mounjaro dosing, side effects, and clinical updates.

Health & Wellness

Beyond the Scale: GLP-1 Users & the Exercise Paradox

While GLP-1 medications have revolutionized weight loss, a recent study indicates a concerning trend: users may be reducing their physical activity. This article explores the findings and emphasizes the continued importance of exercise.

7 min read

Health & Wellness

Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks

Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.

6 min read

Health & Wellness

GLP-1s & Telehealth: Navigating Risks and Ensuring Safety

The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.

6 min read

Same topic: Diabetes Treatment

All Diabetes Treatment articles →

Biotechnology

Arecor CEO on FY25 Highlights: AT278 & GLP-1 Progress

Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.

4 min read

GLP-1 Medications

Why Ozempic Doesn't Work for Everyone: Hidden Genetic Reason Found

Scientists have uncovered why Ozempic and similar GLP-1 drugs don't work for everyone: genetic variants in the PAM gene cause GLP-1 resistance in about 10% of people. Despite higher GLP-1 levels, these individuals show reduced drug effectiveness in lowering blood sugar. This breakthrough could pave the way for personalized treatment strategies.

5 min read

GLP-1 Medications

GLP-1s Insurance Pricing Challenges: Q&A with Whitney Stidom

High demand for GLP-1 medications meets steep pricing and insurance hurdles. In this Q&A, eHealth's Whitney Stidom reveals why 55% of employers cover GLP-1s for diabetes but only 36% for weight loss, plus upcoming policy changes capping costs at $245 monthly for Medicare enrollees. Discover actionable insights on affordability and access.

6 min read

More in Health

Health Policy & Innovation

Ozempic, Wegovy, Mounjaro: Why Rhode Island Medicaid Must Cover Obesity Meds

Rhode Island's strategic health initiatives are commendable, but a recent budget proposal to cut Medicaid coverage for GLP-1 obesity treatments like Ozempic and Wegovy raises serious concerns. This decision, while seemingly a cost-saving measure, risks long-term health consequences and increased healthcare expenditures.

6 min read

Health & Wellness

Ozempic, Mounjaro & More: Bridging the Global Gap for Cheaper Biologics

While generics have revolutionized drug affordability, newer biologics like those used for weight loss and diabetes face unique challenges. A new study reveals how varying international regulations are slowing the adoption of affordable biosimilars, impacting patient access and costs.

6 min read

Health & Wellness

Beyond the Headlines: Navigating Severe GLP-1 Side Effects

Actress Mayim Bialik's recent experience with severe gastrointestinal distress after starting a GLP-1 medication has brought a critical conversation to the forefront: the reality of significant side effects associated with these popular drugs. While GLP-1s offer profound benefits for many, understanding and managing potential adverse reactions is paramount.

7 min read